MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases

H. Kh Haider, Y. Lei, Muhammad Ashraf

Research output: Contribution to journalReview article

24 Scopus citations

Abstract

Cell therapy is fast emerging as a potential therapeutic option in cardiovascular therapeutics. Because of their inherent myogenic differentiation potential, skeletal myoblasts (SkMs) have been extensively assessed in preclinical and clinical studies for their feasibility, safety and effectiveness for myocardial repair. Bioheart Inc is developing MyoCell, autologous SkMs delivered by MyoCath and MyoStar catheter delivery systems, for the treatment of cardiovascular diseases such as myocardial infarction and congestive heart failure. MyoCell is undergoing phase II/III clinical development and has so far demonstrated safety and efficacy, including improvements in cardiac function in phase I/II clinical trials.

Original languageEnglish (US)
Pages (from-to)611-621
Number of pages11
JournalCurrent Opinion in Molecular Therapeutics
Volume10
Issue number6
StatePublished - Dec 2008
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases'. Together they form a unique fingerprint.

  • Cite this